That was it, of course, MM waited for a quiet day, caught me by surprise. There's an interesting post over on the Sage YMB, by a basher, can't say that his point may not have merit:
joe120055 • Mar 25, 2016 12:54 PM Flag
1users liked this postsusers disliked this posts2Reply
The Cambridge based VC firms have been running a profitable Ponzi scheme for years now. Sage is just one of the latest installments. By now, it is a well-oiled machine and goes something like this:
I found it interesting, if you do, go there and read the thread, too long to re-post here. As I type this, we are trading at 5.70 having briefly eclipsed 5.80 on the way back up from 5.55.
And thank you for a comprehensive well written article. Love your handle here, reflects well on your expertise, now confirmed with the article. Keep up the good work, we appreciate it. I keep adding, twice this week, as low as 2.29 and again today at 2.36 after reading your article.
Sentiment: Strong Buy
Four of my stocks were either flat or up, compared to 6 down, this was the highest percentage leader of my losers. O/T take a look at ATHX. The near term catalyst is May 5th ER call, I'll say no more.
Schwab called me yesterday to try to interest me in loaning my shares for a 7% return. I declined to do so, as I oppose the whole paradigm of shorting biotech stocks, seems immoral to try to undermine companies seeking a cure for terrible disease. The shorts want more leverage on this name, do all we can to fight it, refuse to yield to their cause.
You expect positive results in this instance, yet your earlier post I replied to "on a positive note" reads otherwise?
Stock trading down to 1.10 on low volume. Panic sellers, don't understand this capital is necessary for growing the company. I do question the need for it now however, as they have the stock purchase agreement in place with Aspire Capital, that should have given them the legs to have extended this well into next year had they used it. Maybe they didn't like the terms of that agreement? Anyone here have insight?
Thanks for clarifying. Time to buy more AVXL? GALE? Biggest loser is IDRA, my recent sells @ $1.99, 1.97, 1.95, 1.90, 1.85. Today's close $1.71! #$%$! It may test $1.50?
I emailed investor relations, will report here what I learn if I get a reply. They aren't answering calls to the main number and I didn't have another number or name. Disillusioned, upset with this action now, after being led to believe they had sufficient cash on hand $12.54M at 2015 year end, together with Aspire agreement for $15M. That's 27.54 million, what's up?
As did I am so far 237,400 shares have changed hands. I have an open order at 2.30 with partial fill now. I just can't see where this can go wrong with what we know now, and the upside is huge.
The commercialization stage is often fraught with risk and doubt, so how is it with a market that is slow to adopt new paradigms, that you remain so bullish? I am long and now down 20%, hope you are correct.
Expecting a different result will only drive you nuts (sic). $4.40 in December 2015, $1.66 today, the stock is down 62% since, in 4.5 months. Until the pipeline matures, and they come up with something in humans that impresses investors, and adheres to the value of their stock, the most you can expect is counter-trend 'pops' from time to time, that fade. The market remains bearish on biotech, especially early stage developmental small caps. Of course, there are exceptions, like CPXX. Is IDRA the next exception?
I missed the early, on-sale shares, but managed to build a floor under our stock at 2.30 for most of the last 90 minutes. By adding 17,000 shares, I brought my average price down to 2.34. I think I'm set now, but always can jettison some other positions if this starts hitting a forward stride. What an interesting opportunity, to be here at this stage, just prior to the rocket launch. Very excited to hear what Gil and Company have prepared for us next week. Have a terrific weekend longs!
Jerry, I am new here in last few weeks but it's hard to temper one's enthusiasm, you are obviously a good guy with best intentions and you added value today by bringing this posted information forward. The story is big here, and it's happening and verifiable. Mark's comment above is appreciated in balance, we have to keep it real and also explore the challenges. Too much of only showing the prospective upside gets some people in over their head and we want a balanced presentation here. Adding today was a joy and with supreme confidence. Of 10 stocks I hold this was one of two green, and I was adding big time to make it so. GLAL.
Friday was lousy again after a partial lift Thursday. This isn't going to my script just sayin'. I hate to acknowledge that the short trade here is alive and not to be ignored or taken for granted. Shorts on biotech stocks are the lowest form of life, but maybe they are a necessary evil to keep it real, without which there would be incessant pumping. I'm all for keeping it real, but Ganaxolone is going to rock in trials, so they will get their time in the sand pit soon enough and I will still be holding my shares long. RIP losers!
Never have I heard nor would I think that is the primary motivation behind a cash raise. They must have an agenda that is timely and opportune, but we all deserve an explanation as to the Aspire agreement, what happened with that AND the $12.45M they had in cash at year-end 2015. It was unexpected, and shares reacted accordingly. Let's hope shorts covered, otherwise greed will catch them later.
Thanks George, nice to have the links all in one post. Investor's may forget what they read, but what they watch as proof of concept and emerging efficacy in real people regaining their faculties and personalities, with complex motor skills returning, that isn't easily forgotten when we get attacked by the dark side.